NewsDialy
A drug designed to interrupt a specific inflammation signal in the body reduced measurable signs of that inflammation in a midstage clinical trial.
Biomarkers, the proteins used to track whether inflammation is active inside a patient, fell consistently among participants, and higher doses produced greater drops.
The drug is called pacibekitug; Novartis recently acquired it, and the results were presented Saturday at the European Society of Cardiology's annual meeting in Munich.
What the TRANQUILITY data show The study's name is the Phase 2 TRANQUILITY trial. Phase 2 is the midstage test that asks whether a drug is working at the right dose; Phase 1 only establishes whether it is safe.
Keep reading